BCRX Share Price

Open 4.44 Change Price %
High 4.53 1 Day 0.07 1.58
Low 4.38 1 Week 0.00 0.00
Close 4.50 1 Month -0.55 -10.89
Volume 1020841 1 Year -0.84 -15.73
52 Week High 9.25
52 Week Low 3.95
BCRX Important Levels
Resistance 2 4.64
Resistance 1 4.58
Pivot 4.47
Support 1 4.42
Support 2 4.36
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)

BCRX Technical Analysis 4
As on 31st Oct 2017 BCRX Share Price closed @ 4.50 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 5.94 & Sell for SHORT-TERM with Stoploss of 4.97 we also expect STOCK to react on Following IMPORTANT LEVELS.
BCRX Target for June
1st Target up-side 5.17
2nd Target up-side 5.64
3rd Target up-side 6.11
1st Target down-side 3.83
2nd Target down-side 3.36
3rd Target down-side 2.89
BCRX Other Details
Segment EQ
Market Capital 131269904.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biocryst.com
BCRX Address
4505 Emperor Boulevard
Suite 200
Durham, NC 27703
United States
Phone: 919-859-1302
Fax: 919-859-1314
BCRX Latest News
Interactive Technical Analysis Chart BioCryst Pharmaceuticals, Inc. ( BCRX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on BioCryst Pharmaceuticals, Inc.
BCRX Business Profile
BioCryst Pharmaceuticals, Inc. (BioCryst), incorporated in 1986, is a biotechnology company that designs, optimizes and develops drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on therapeutic areas. Peramivir is its product, which is a neuraminidase inhibitor for the treatment of patients with influenza. The Company has two purine nucleoside phosphorylase (PNP) inhibitors that are in development, BCX4208 and forodesine. Intravenous (i.v.) peramivir, for the treatment of patients with influenza, has been approved in Japan and Korea. In addition, as of December 31, 2011, i.v. peramivir was in Phase III development. As of December 31, 2011, the Company was developing i.v. peramivir, through contract from the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (BARDA/HHS). The Company also has various regional collaborations for the development and commercialization of peramivir in Taiwan and Israel, as well as government stockpiling agreements in Europe, Russia, Canada and Singapore. Peramivir is an intravenously administered anti-viral agent. Peramivir inhibits the interactions of influenza neuraminidase. Peramivir is an inhibitor of influenza A and B viruses, including strains of influenza viruses. As of December 31, 2011, BioCryst was enrolling patients in its final i.v. peramivir Phase III trial, clinical trial 301. On January 13, 2011, the Company announced results from its completed 303 clinical trial. BCX4208 is an oral PNP inhibitor. As of December 31, 2011, the Company was conducting a Phase I trial to evaluate the metabolic profile of BCX4208 and were also enrolling patients into the 12-week phases II BCX4208-204 trial in patients with gout and moderately impaired renal function. Forodesine is an orally-available transition-state analog PNP inhibitor. Forodesine has been granted orphan drug status by the United Sates Food and Drug Administration (FDA) for three indications: T-cell non-Hodgkin's lymphoma, including cutaneous t-cell lymphoma, (CTCL); chronic lymphocytic leukemia (CLL) and related leukemias, including T-cell prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia; and for treatment of B-lymphoblastic leukemia (B-ALL). The Company's pre-clinical compounds include BCX4161, an oral prophylactic drug for hereditary angioedema, and BCX5191, an adenine nucleoside analog targeting viral ribonucleic acid (RNA) polymerase for the treatment of hepatitis C.